Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer
OncoReview · 2020
DOI: 10.24292/01.or.120250320 ↗Kurz gefasst
Fallbericht in der Zeitschrift OncoReview, 2020. Verfasst von Marlena Orlikowska. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival
Zitieren
APA
Orlikowska, M. (2020). Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer. OncoReview. https://doi.org/10.24292/01.or.120250320
Vancouver
Orlikowska M. Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer. OncoReview. 2020. doi:10.24292/01.or.120250320
BibTeX
@article{Orlikowska2020,
author = {Orlikowska, Marlena},
title = {Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer},
journal = {OncoReview},
year = {2020},
doi = {10.24292/01.or.120250320}
}
EUVIMED